Boston Scientific (BSX) Short term Debt (2009 - 2026)

Boston Scientific has disclosed Short term Debt across 18 years of filings, most recently posting $41.0 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $41.0 million, down 94.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.0 million (down 94.72% YoY), and the FY2025 annual result was $299.0 million, down 83.18% from the prior year.
• Short term Debt came in at $41.0 million for Q1 2026 at Boston Scientific, down from $299.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $1.8 billion in Q4 2024 to a low of $20.0 million in Q3 2022.
• The 5-year median for Short term Debt is $510.0 million (2023), against an average of $631.5 million.
• Across the five-year window, Short term Debt surged 2555.0% in 2023 and plunged 94.72% in 2026, its largest moves.
• Boston Scientific's Short term Debt stood at $20.0 million in 2022, then soared by 2555.0% to $531.0 million in 2023, then surged by 234.84% to $1.8 billion in 2024, then sank by 83.18% to $299.0 million in 2025, then sank by 86.29% to $41.0 million in 2026.
• The last three Short term Debt figures came in at $41.0 million (Q1 2026), $299.0 million (Q4 2025), and $483.0 million (Q3 2025), per Business Quant data.